Presidential Symposium II
Invited Discussant LBA6_PR and LB7_PR
Date
29 Sep 2019Session
Presidential Symposium IIPresenters
Sibylle LoiblAuthors
S. LoiblAuthor affiliations
- Department Of Medicine And Research, German Breast Group (GBG) Forschungs GmbH, 63263 - Neu-Isenburg/DE
Resources
Resources from the same session
1605 - MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer
Presenter: George Sledge
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
7184 - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
Presenter: Dennis Slamon
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
1812 - KEYNOTE-522: Phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
Presenter: Peter Schmid
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
2520 - Phase 3 study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer
Presenter: Veronique Dieras
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA8_PR and LBA9
Presenter: Sherene Loi
Session: Presidential Symposium II
Resources:
Slides
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.